Janssens P, Mitine C, Beauduin M, Scalliet P
Department of Radiation Oncology, Antwerp University (UIA), Belgium.
Eur J Cancer. 1994;30A(5):642-5. doi: 10.1016/0959-8049(94)90536-3.
The purpose of this communication was to explore which situations in radiotherapy might benefit from concomitant administration of haematopoietic growth factors (HGF). Only large-field radiotherapy is likely to induce bone marrow depression, such as irradiation of Hodgkin's disease. Therefore, we studied 122 patients irradiated for Hodgkin's disease, looking at peripheral blood cell count before, during and after the treatment. One hundred and four treatments were preceded by chemotherapy (MOPP and/or ABVD) and the radiation dose was between 36 and 44 Gy in 2 Gy per fraction sessions. Severe leucopenia (grade III WHO) was very uncommon and justified treatment interruption only twice. In both cases, it was paired with thrombocytopenia. No infection developed. It is concluded that when radiotherapy is used alone, prophylactic use of HGFs does not seem justified. This, of course, does not apply to radiochemotherapy combinations, although thorough investigations in this field are still awaited.
本通讯的目的是探讨放射治疗中的哪些情况可能受益于造血生长因子（HGF）的联合应用。只有大野放疗可能会导致骨髓抑制，如霍奇金病的放疗。因此，我们研究了122例接受霍奇金病放疗的患者，观察治疗前、治疗期间和治疗后的外周血细胞计数。104例治疗前接受了化疗（MOPP和/或ABVD），放射剂量在36至44 Gy之间，每次分割剂量为2 Gy。严重白细胞减少（WHO III级）非常罕见，仅两次导致治疗中断。在这两例中，均伴有血小板减少。未发生感染。结论是，单独使用放疗时，预防性使用HGF似乎没有道理。当然，这不适用于放化疗联合应用，尽管该领域仍有待深入研究。
